Mutational processes behind breast cancer
Researchers develop mutation catalogue to discover the processes behind 21 breast cancers
In a study published in Cell online on 17 May, researchers catalogue all the mutations in the genomes of 21 breast cancers and use the information to identify the mutational processes responsible for the development of these tumours.
All cancers are due to mutations – changes in DNA that occur in cells of the body during the course of a person’s lifetime. Chemicals in tobacco smoke damage DNA in lung cells, causing mutations that lead to lung cancer. Similarly, sunlight damages DNA in skin cells causing mutations that lead to skin cancer. However, we have very limited knowledge of the mechanisms generating mutations in most other cancer types.
A total of almost 200,000 mutations in the genomes of the 21 breast cancers was found by the team, led by researchers from the Wellcome Trust Sanger Institute. By examining the mutations from each cancer, they could discern different patterns of mutation, which appear to represent traces of past mutational mechanisms that have acted on the genomes of individual cells during the life of the patient. These traces are like archaeological imprints left in the DNA of the cancer cell by mutational processes which could have been active many years before the cancer came to attention. Previously, there was little, if any, knowledge about most of these processes and the 21 breast cancer samples seem to have been assaulted by different combinations of them.
“What emerges is a really complex landscape of mutation, where each cancer seems to have been generated by a different combination of mutation processes.
“In our analyses, we have excavated these cancer genomes, in a similar manner to an archaeological dig, and uncovered patterns of mutation that had never been seen before. We do not know for sure what the underlying biological mechanisms causing these mutation patterns are. However, we suspect certain processes in normal cells that generate mutations have been overactive and simply caused too many mutations, hence leading to cancer. We do not think that these mutation patterns are due to external exposures like tobacco smoke or sunlight, which are known to cause mutations and cancer, but more likely are due to defective internal cellular machinery. However, further work needs to be conducted to confirm this view.”
Professor Mike Stratton Lead author and Director of the Wellcome Trust Sanger Institute
One of the novel mutation mechanisms is a remarkable process that leads to large numbers of mutations in small regions of the genome. The authors call this ‘kataegis’ (from the Greek for thunderstorm): although never described before, kataegis was remarkably common occurring, to some extent, in the genomes of 13 of the 21 breast cancers. The dense bursts of mutations in each patch of kataegis are likely to have occurred at one point in time rather than accumulated in a step-wise fashion over the lifetime of the cancer.
“In kataegis, a large number substitution mutations occur very close together in the genome. They show a distinguishing mutational motif and frequently co-occur with large-scale rearrangements: it is a unique mutational pattern.
“We expect that this phenomenon is not restricted to breast cancer and might operate in other cancers. Current sequencing technologies allow us to make these discoveries which were hidden from us before.”
Dr Serena Nik-Zainal First author from the Wellcome Trust Sanger Institute
The pattern of mutations in kataegis is highly distinctive, and the team speculate that there is a relationship between kataegis and a protein family, APOBEC. Members of this family can induce similar mutational changes in experimental systems and are thought to play a role in defence against viruses.
The mutational processes identified by the researchers allowed them to distinguish cancers from women with known BRCA1 and BRCA2 mutations from other, more common or sporadic, breast cancers. The team speculate that these distinguishing mutational patterns might be present in other types of cancer and could help to predict response to treatments such as PARP inhibitors to which BRCA1/BRCA2 cancers are particularly sensitive.
“Our results highlight the power of whole cancer genome sequencing in our quest to understand the fundamental processes that lead to the development and spread of breast cancer. To understand these processes more comprehensively – to build the full picture we need of the processes behind breast cancer genetics – we will need many hundred samples of breast cancer genomes sequenced and catalogued.”
Dr Peter Campbell Head of Cancer Genetics and Genomics at the Wellcome Trust Sanger Institute
A full list of funding agencies can be found in the papers.
A full list of participating centres can be found in the papers.
Breakthrough Breast Cancer
Breakthrough Breast Cancer is dedicated to improving and saving lives through finding the causes of breast cancer, enabling early detection, ensuring precise diagnosis, discovering new and better treatments and improving medical services. Breakthrough Breast Cancer funds groundbreaking research, campaign for better services and treatments and raise awareness of the signs and symptoms of breast cancer. Through this work the charity believes passionately that breast cancer can be beaten and the fear of the disease removed for good.
The Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.
The Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests.
13 Mar 2023
New research writes the rules on CRISPR activation
Researchers have started to map out the rules on how to use CRISPR activation techniques in the most effective way, assisting ...
8 Mar 2023
Equality, Diversity and Inclusion champions recognised at Best Practice Awards
The Wellcome Genome Campus holds its annual awards for Best Practice in supporting Equality, Diversity and Inclusion in science, in celebration ...